FDA Approves Alvotech Process That More Than Doubles SIMLANDI Batch Output
On October 20, 2026, the U.S. Food and Drug Administration approved Alvotech’s Process 2.0 for manufacturing SIMLANDI, its adalimumab biosimilar, at the DSM2 suite in Reykjavik. The process more than doubles drug-substance output per batch without changing upstream manufacturing scale. Alvotech said validation showed comparability with the prior process while maintaining product quality, safety and efficacy.
Why it matters
Alvotech says the process will let it produce the same quantity in fewer batches, freeing capacity for other biosimilars and improving flexibility to address demand. The approval changes manufacturing capability, but the materials do not provide an implementation date or estimate of per-unit savings.
Key facts
- 1The FDA approved Process 2.0 for manufacturing SIMLANDI drug substance at Alvotech’s DSM2 manufacturing suite in Reykjavik, Iceland. stocktitan.net
- 2Process 2.0 more than doubles drug-substance output per batch without changing the upstream manufacturing scale. stocktitan.net
- 3Alvotech said the validated process maintained product quality, safety and efficacy and was comparable with the previously approved process. stocktitan.net
- 4The FDA approval was announced by Alvotech on October 20, 2026. stocktitan.net
Open questions
- The materials do not establish when Process 2.0 will be implemented or when the first commercial batches will be produced.
- The materials do not quantify any per-unit savings or margin change from the process.
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.